Interestingly, one study found a strong correlation between the objective response rate to anti–PD-1 or anti–PDL1 therapy in 27 tumor types, including ovarian cancer, and overall tumour mutational burden [303]. This evidence concerns the gene PDCD1 and ovarian cancer.